SCHEMBL30051599

SCHEMBL30051599

Nc1ncnc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)OC(=O)[C@@H](N)Cc2ccccc2)[C@@H](O)[C@H]1O

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
P2RY1 P47900 7/20 0.69
P2RY2 P41231 4/20 0.69
SRC P12931 2/20 0.69
SMN1; SMN2 Q16637 2/20 0.69
P2RX1 P51575 2/20 0.69
P2RX3 P56373 2/20 0.69
ALDH1A1 P00352 2/20 0.69
P2RX4 Q99571 1/20 0.69
P2RX2 Q9UBL9 1/20 0.69
TAS1R3 Q7RTX0 2/20 0.67
TAS1R1 Q7RTX1 2/20 0.67
P2RY12 Q9H244 1/20 0.67
TRPM2 O94759 2/20 0.66
DNPH1 O43598 1/20 0.66
PRKAB2 O43741 1/20 0.66
LDHA P00338 1/20 0.66
ADRB2 P07550 1/20 0.66
FBP1 P09467 1/20 0.66
ADORA1 P30542 1/20 0.66
PRKAG1 P54619 1/20 0.66

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4945718 1.00 P2RY1 (0.69) P2RY1P2RY2SRCSMN1; SMN2P2RX1
SCHEMBL30903856 0.93 P2RY1 (0.68) P2RY1P2RY2SRCSMN1; SMN2P2RX1
SCHEMBL347342 0.93 P2RY1 (0.68) P2RY1P2RY2SRCSMN1; SMN2P2RX1
SCHEMBL17148064 0.92 P2RY1 (0.67) P2RY1P2RY2SRCSMN1; SMN2P2RX1
Adenosine Phosphate SCHEMBL15671063 0.91 P2RY1 (0.76) P2RY1P2RY2SRCSMN1; SMN2P2RX1
SCHEMBL18423487 0.89 P2RY1 (0.73) P2RY1P2RY2SRCSMN1; SMN2P2RX1
Adenosine Triphosphate SCHEMBL3515197 0.88 P2RY1 (0.70) P2RY1P2RY2SRCSMN1; SMN2P2RX1
SCHEMBL21067651 0.86 P2RY1 (0.60) P2RY1P2RY2SRCSMN1; SMN2P2RX1
SCHEMBL27695784 0.86 P2RY1 (0.63) P2RY1P2RY2SRCSMN1; SMN2P2RX1
Adenosine Phosphate SCHEMBL1050410 0.86 P2RY1 (0.76) P2RY1P2RY2SRCSMN1; SMN2P2RX1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12570688-B2 Activated cysteine-directed polypeptide ligation technique THE TEXAS A&M UNIVERSITY SYSTEM (US) 2026-03-10 US disclosed
US-20230002442-A1 AN ACTIVATED CYSTEINE-DIRECTED POLYPEPTIDE LIGATION TECHNIQUE THE TEXAS A&M UNIVERSITY SYSTEM 2023-01-05 US disclosed
EP-4085139-A1 AN ACTIVATED CYSTEINE-DIRECTED POLYPEPTIDE LIGATION TECHNIQUE The Texas A&M University System (US) 2022-11-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12570688-B2 Activated cysteine-directed polypeptide ligation technique PTMS, LNPEP, ANPEP P2RY1 4101/4885P2RY2 3502/4885SRC 505/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.